Jeffrey W. Albers, Director at Blueprint Medicines Corp (BPMC), sold 22,722 shares at $109.11 ($2.5M) on 2025-01-21, disclosed to the SEC on 2025-01-23.
Scheduled sale ($2.5M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $109.11 | 7,561 | $825K | 33.2% |
| 2 | $109.11 | 7,561 | $825K | 33.2% |
| 3 | $109.92 | 7,400 | $813K | 32.7% |
| 4 | $110.61 | 200 | $22K | 0.9% |
| Total | $109.39 avg | 22,722 | $2.5M | 100% |
| Filing → |
| KYMR | SELL | 2025-10-14 | $296K | — | Filing → |
| KYMR | SELL | 2025-06-03 | $311K | — | Filing → |
| BPMC | SELL | 2025-05-29 | $572K | — | Filing → |